Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab +/- Docetaxel Before Prostatectomy in Prostate Cancer
NCT00448097Phase 2Terminated
- Sponsor
- Houston Methodist Research Institute
- Start
- Feb 2007
- Primary completion
- Jun 2008
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in prostate cancer (PCa), sponsored by Houston Methodist Research Institute. Started Feb 2007; status: terminated.
02
Drugs
cetuximab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00448097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00448097.